Anti-ZnT8 Antibody (mAb43)

Cat. No.: HY-P992159: Ficha de datos
FAQs
Technical Support

Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes.

Para uso exclusivo en investigación. No vendemos a pacientes.

Anti-ZnT8 Antibody (mAb43) Estructura química

Tamaño		Stock
MOQ		Minimum order quantity
1 mg		Obtener un presupuesto
5 mg		Obtener un presupuesto
10 mg		Obtener un presupuesto
Other size		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Recomendaciones destacadas

•Related Small Molecules:

•Related Proteins:

Actividad biológica
Pureza y Documentación
Referencias
Revisión del cliente

Descripciòn

In Vivo

Anti-ZnT8 Antibody (mAb43) (5 mg/kg; i.v.; weekly; up to 25 weeks) administered from 10 weeks of age provides 100% sustained protection against spontaneous type 1 diabetes onset in female NOD mice through 35 weeks^[1].
Anti-ZnT8 Antibody (mAb43) (5 mg/kg; i.v.; weekly; up to 26 weeks) administered from 14 weeks of age provides prolonged protection against spontaneous type 1 diabetes in female NOD mice^[1].
Anti-ZnT8 Antibody (mAb43) (5 mg/kg; i.v.; weekly; 11 weeks) has no detectable adverse effects on β-cell function, glucose homeostasis, or insulitis in male B6 db mice with obesity-induced type 2 diabetes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NOD/ShiLtJ (female, 10 weeks old at treatment initiation)^[1]
Dosage:	5 mg/kg
Administration:	i.v.; weekly; up to 25 weeks
Result:	Maintained euglycemia through 35 weeks of age in all 64 treated mice, with only one mouse experiencing a transient hyperglycemic episode that resolved to FBG <250 mg/dL. Achieved 100% nondiabetic rate, compared to 0% of control mice. Exhibited significantly higher β-cell mass than diabetic control mice at all ages. Showed median insulitis severity between that of control mice with acute or progressive T1D onset at 20 weeks of age; extending treatment to 35 weeks resulted in significant clearance of destructive insulitis. Achieved complete insulin autoantibody (IAA) negativity by 35 weeks of age. Significantly increased the number of CD4⁺FoxP3⁺CD25⁺ regulatory T cells (Tregs) within pancreatic islets, with no significant changes in total CD4⁺ T cells. Shifted islet-residing CD4⁺ T cells toward higher FoxP3 expression without altering immune cell subsets or phenotypes in pancreatic lymph nodes or spleens.

Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.

Pureza y Documentación

Inhibitory Antibodies User Guide (603 KB)

Referencias

[1]. Kasinathan D, et al. Cell-Surface ZnT8 Antibody Prevents and Reverses Autoimmune Diabetes in Mice. Diabetes. 2024;73(5):806-818.